The study “Rosehip Inhibits Xanthine Oxidase Activity and Reduces Serum Urate Levels in a Mouse Model of Hyperuricemia” by Hidetomo Kikuchi et al. (2017) examined whether rosehip, the fruit of Rosa canina L., could affect urate metabolism in a meaningful way. This summary is a paraphrase of the scientific paper only. The researchers tested rosehip extracts made with hot water, ethanol, and ethyl acetate to assess their ability to inhibit xanthine oxidase, then tested the hot-water extract in mice with potassium oxonate-induced hyperuricemia, and also checked whether the same extract strongly interfered with cytochrome P450 3A4, an enzyme linked to many herb-drug interactions.

The scientific paper explains that rosehip has long been used as both a food and a traditional remedy. The authors note that rosehip is rich in vitamin C and also contains vitamins, minerals, sugars, fatty acids, and flavonoids. They also explain that rosehip has traditionally been used for colds, infections, inflammatory conditions, and disorders of urate metabolism, but that its urate-related effects had not been described in sufficient detail before this study.

The paper also gives an important reason for studying urate. In humans, urate is the end product of purine metabolism, and xanthine oxidase (XO) catalyzes its formation from hypoxanthine in two enzymatic steps. When urate production and excretion fall out of balance, hyperuricemia can develop. The paper links that imbalance to gout, kidney stones, and faster progression of kidney and cardiovascular disease.

A second reason the study matters is safety. The authors point out that many foods and herbs can affect drug-metabolizing enzymes, and they chose to test cytochrome P450 3A4 (CYP3A4) because it is a major drug-metabolizing enzyme. In the paper’s words, this was important from an “herb-drug interaction perspective.” That gave the study both an effectiveness question and a safety question.

The paper explains that most mammals break urate down further with uricase, but humans do not. To more closely mimic this aspect of human purine metabolism, the researchers used potassium oxonate (PO), a uricase inhibitor, to generate a mouse model of hyperuricemia. This matters because it allows the team to test whether rosehip hot-water extract could lower serum urate in a model that more closely resembles the human situation.

The authors also explain why they chose the hot water extract for the animal study. Rosehip is often consumed as herbal tea, and the hot-water extract yielded much more than the other extraction methods. That made it the most practical extract to carry from the lab test into the mouse experiment.

The scientific paper used three extract types: hot water, ethanol, and ethyl acetate. The hot water extract was prepared by decocting rosehip powder in water at 100°C for 30 minutes, then cooling, filtering, freeze-drying, and dissolving the dried sample. The ethanol and ethyl acetate extracts were made by room-temperature agitation for 2 hours, followed by filtration, evaporation, and preparation in dimethyl sulfoxide (DMSO). The reported yields were 65.2% for the hot water extract, 5.66% for the ethanol extract, and 0.85% for the ethyl acetate extract.

To measure xanthine oxidase inhibition in vitro, the researchers mixed the enzyme, buffer, xanthine substrate, and varying concentrations of rosehip extract, then measured urate production with a commercial kit. They calculated half-maximal inhibitory concentration (IC50) values from those curves. To test urate-lowering in vivo, they used male ddY mice with potassium oxonate-induced hyperuricemia and compared vehicle, allopurinol, and hot-water rosehip extract groups at 2, 4, 6, and 8 hours. To assess potential interaction risk, they measured CYP3A4 activity in vitro using a recombinant enzyme and high-performance liquid chromatography (HPLC) to assess testosterone metabolism.

The paper found that all three rosehip extracts inhibited xanthine oxidase activity in a dose-dependent way. The IC50 values were 259.6 ± 50.6 µg/ml for the hot water extract, 242.5 ± 46.2 µg/ml for the ethanol extract, and 1,462.8 ± 544.2 µg/ml for the ethyl acetate extract. The study reports that the hot water and ethanol extracts showed significantly stronger inhibition than the ethyl acetate extract.

This is one of the paper’s clearest findings. It means the extraction method mattered. The authors suggest that solvent polarity may help explain the difference, and they connect the stronger effect to rosehip’s phenolic phytochemicals. They note that “polyphenols, flavonoids and saponins are potent XO inhibitors,” then say that identifying the exact XO-inhibiting constituents in rosehip was still underway.

The mouse experiment moved the findings beyond a test tube. Potassium oxonate increased serum urate levels in control mice, confirming that the hyperuricemia model was working. The 5 mg/kg allopurinol group showed the strongest urate-lowering across time points, while the 1 mg/kg allopurinol group and the 1X rosehip hot water extract group both showed significantly lower serum urate than the control group. The paper states that there was no significant difference between the 1 mg/kg allopurinol group and the 1X rosehip extract group at each measured time point.

That comparison matters because the authors interpret it as evidence that the 1X hot water rosehip extract reduced serum urate “to the same extent” as 1 mg/kg allopurinol in this mouse model. The lower 0.5X rosehip extract group showed a weaker effect, with a significant difference from control only at 8 hours. So the paper supports a dose-dependent urate-lowering effect, but it was stronger with the full-strength hot-water extract than with the half-strength version.

The safety-related finding was more restrained. The hot water rosehip extract tended to reduce CYP3A4 activity with increasing dose, but the decrease was not significant. At the highest tested concentration, 1 mg/ml, the extract inhibited only about 40% of CYP3A4 activity, and the IC50 was reported to be greater than 1 mg/ml.

The authors interpreted this as a weak effect. They wrote that the risk of interaction between hot water rosehip extract and CYP3A4 substrate drugs “appears to be low.” That does not mean zero risk in every real-world setting, but within this scientific paper, the in vitro signal for CYP3A4 interference was limited.

The scientific paper supports the idea that rosehip hot-water extract may have urate-lowering potential through inhibition of xanthine oxidase. It also supports the idea that hot water extraction may be a practical approach, since it matched traditional tea-like use and had a much higher extraction yield than the other solvents. Those two points make the hot water extract the most relevant form in this study.

At the same time, the paper is still preclinical. The xanthine oxidase tests were performed in vitro, and the urate-lowering results were obtained in mice, not humans. That means the study gives an early signal, not final clinical proof. The authors themselves frame rosehip hot water extract as a “promising candidate” rather than a confirmed therapy.

A final point is balance. The paper is positive about the findings, but it does not claim that rosehip replaces allopurinol in human care. The strongest careful reading is this: rosehip hot water extract showed measurable xanthine oxidase inhibition, lowered serum urate in a mouse hyperuricemia model, and showed little effect on CYP3A4 in the assay used, making it worth further study as a functional food or a supportive therapeutic lead.

This paraphrased summary of the scientific paper points to one main takeaway: rosehip, especially as a hot-water extract, showed significant xanthine oxidase inhibition in vitro and lowered serum urate levels in hyperuricemic mice, while only weakly affecting CYP3A4 in the lab test used here. Based on the study alone, rosehip appears promising as an early functional food candidate for high urate research, but the evidence in this paper remains preclinical and should be read as a foundation for further study, not as definitive human evidence.